The city of Alabaster is clearing the way for a new fire station near the intersection of Highway 68 and Simmsville Road. In May 2024, the city of Alabaster purchased around 4.8 acres of land near the ...

Eli Lilly's (NYSE: LLY) big problem is its success in the GLP-1 drug space. Its Mounjaro (for diabetes) and Zepbound (for weight loss) drugs grew sales by 99% and 175%, respectively, in 2025. It's ...

This week's show was recorded in Bloomington, Indiana with host Peter Sagal, judge and scorekeeper Bill Kurtis, Not My Job guest Lilly King and panelists Alonzo Bodden, Josh Gondelman, and Faith Salie ...

Novo Nordisk’s experimental weekly shot CagriSema was shown to lead to less dramatic weight loss compared to rival Lilly’s Tirzepatide, the drug behind Zepbound and Mounjaro, in an 84-week trial, Novo ...

Both Novo Nordisk and Eli Lilly are grappling with pricing pressure in the U.S., but their 2026 outlooks are diverging sharply. While Novo is bracing for a sales decline, Lilly sees revenue charging ...

Eli Lilly & Co. provided an upbeat sales forecast for the year Wednesday as strong demand for its weight loss drug cemented its position at the top of the obesity market. The guidance was a sharp ...

Eli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's quarterly earnings results, state of the weight-loss drug market, drug pipeline, 2026 outlook, and more. Got a confidential news ...

The Alabaster YMCA will close at the end of May 2026, ending years of service to the community, according to a statement from the YMCA of Greater Birmingham. The YMCA said ongoing financial losses ...

Evangeline Lilly is preparing for her future, following her traumatic brain injury (TBI) in 2025. The actress revealed in May of last year that she sustained a horrific injury after falling at the ...

Eli Lilly and Viking Therapeutics both operate in the high-growth field of obesity drugs. This market is forecast to reach almost $100 billion by the end of the decade. As mentioned, Lilly's weight ...

GLP-1 giant Eli Lilly has once again taken to the medium of short film to deliver an important message about obesity. In early 2024, the Big Pharma debuted a pair of unbranded shorts entitled “Big ...

Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has now introduced a pill version of its GLP-1 weight loss drug. Eli Lilly's ...